Dr. Gordon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Biesterfield Rd.
Cancer Institute Bld. #5, Ste. 210
Elk Grove Village, IL 60007Phone+1 847-437-3312Fax+1 847-981-5917
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1997 - 2000
Yale-New Haven Medical CenterResidency, Internal Medicine, 1993 - 1996
Emory University School of MedicineClass of 1993
Certifications & Licensure
IL State Medical License 1994 - 2026
MD State Medical License 1983 - 2022
FL State Medical License 2000 - 2005
CT State Medical License 1995 - 1997- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
Publications & Presentations
PubMed
- 209 citationsVenetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour
Journal of Clinical Oncology. 2018-05-01 - 42 citationsPhase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung CancerCharles M. Rudin, Ann M. Mauer, Martin Šmakal, Rosalyn A. Juergens, Stanislav Spelda
Journal of Clinical Oncology. 2011-03-10 - 16 citationsA phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.Everett E. Vokes, Gary S. Gordon, Charles M. Rudin, Ann M. Mauer, S. Watson
Investigational New Drugs. 2001-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
